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• In this volume of Biomedical Reviews, Rogers and 
Hermann (1) present an interesting model for the regulation of 
gastrointestinal function by two peptides, neuropeptide Y 
(NPY), and peptide YY (PYY), both of which belong to a 
related group of peptides known as the pancreatic polypeptide 
(PP)-fold family of peptides. In this review, largely of their 
own innovative work, they develop the hypothesis that PYY, 
acting as a humoral (hormonal) agent, may be a maj or inhibitory 
factor in the regulation of the upper gastrointestinal tract. In 
contrast, NPY would appear to be a maj or excitatory transmitter. 
How can two structurally homologous peptides produce such 
divergent actions? 
The explanation proposed in this review is that PYY is released 
from within the gastrointestinal tract, but exerts its effects 
through an action on the dorsal vagal complex (DVC), which 
consists of the dorsal vagal nucleus, the nucleus of the tractus 
solitarius (NTS), the area postrema (AP), and other subnuclei. 
In this area, PYY acts preferentially on Y2 receptors leading to 
inhibition of gastrointestinal activity. In contrast, it is proposed 
that NPY is released from nerve terminals within the DVC, and 
acts preferentially on Yl receptors leading to excitation of the 
upper gastrointestinal tract. This hypothesis is discussed in the 
light of a recent observation that PYY released from the ileum is 
rapidly cleaved by a diaminopeptidase (DAP-IV) to produce a 
fragment (PYY 13-36) that is a potent and specific Y2 agonist 
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(2). Thus, two structurally related peptides with similar 
biological activity profiles can exert totally divergent 
physiological effects, based on their relative affinities for 
distinct receptor subtypes and on their different sites of 
release, and therefore have a different route whereby they 
are able to modify the activity of neurons within the DVC. 
While the evidence compiled by these authors strongly 
supports this attractive hypothesis, further proof is required 
as they themselves admit. In particular, they draw attention to 
a perceived need for a histoanatomical demonstration that Yl 
and Y2 receptors are located on different components of the 
DVC, and for aneurophysiological verification of this. Implicit in 
this suggestion is the assumption that different populations of 
DVC neurons are responsible for excitation and inhibition of 
gastrointestinal activity. This is undoubtedly so, but does 
excitation or inhibition within the gastrointestinal tract depend 
solely upon activation of these two distinct pathways? Probably 
not. 
Neurophysiological studies of the DVC based on micro-
electrode recordings from the NTS or recording from single 
vagal efferent fibres (3) have revealed that DVC neurons are 
usually tonically active and may be excited or inhibited by any 
specific sensory input. Therefore, it seems probable that 
excitation or inhibition within the gastrointestinal tract may 
not only depend upon activation of the appropriate descending 
excitatory or inhibitory pathway, but perhaps may depend also 
on reciprocal inhibition of the opposing pathway (4). Should 
histological studies reveal a differential distribution of Yl and 
Y2 receptors on neurochemically distinct DVC neurones, this   
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would, of course, strongly support the authors' hypothesis and, 
moreover, would suggest that the different physiological effects 
of NPY and PYY are due to their ability to activate different 
descending vagal pathways. However, the existence of Yl and 
Y2 receptors on the same neurons does not invalidate the 
central hypothesis since the receptors could be linked to a 
different intracellular messenger system leading to either 
excitation or inhibition of the DVC neurons. In many ways, a 
neurophysiological analysis of the actions of highly selective 
Y1 and Y2 agonists and antagonists would provide the most 
definitive proof of the hypothesis. 
One of the intriguing concepts underlying this hypothesis is 
the notion of humoral regulation of central nervous system 
function. This is not aunique concept, since similar mechanisms 
have been proposed for the regulation of gastrointestinal and 
other autonomic functions as well as for the regulation of 
complex behaviours, such as food and water intake, emesis, 
fever, etc. However, in all these cases, including the mechanism 
proposed by Rogers and Hermann (1), a major question that 
needs to be addressed is how does the humoral agent 
communicate with the CNS neurons? Does it act peripherally 
to stimulate primary afferent nerves? Does it cross the blood-
brain barrier or act within the cerebroventricular system on 
receptors located at the site of circumventricular organs? All 
three of the above possibilities could explain the actions of 
putative hormonal modulators of neural function. 
For example, several studies have shown that circulating peptides 
such as cholecystokinin can activate vagal sensory fibres in the 
muscle wall of the stomach (5) or the mucosa of the small 
intestine (6) by a direct action on the nerve endings. This leads to 
activation of certain areas of the caudal brain stem and 
hypomalamus as revealed by fos immunohistochemistry (7). 
Certain emetic substances are believed to act on a chemore-
ceptor trigger zone within the DVC, either by crossing the 
blood-brain barrier or by acting on cells lining the wall of the 
fourth ventricle. Recently, we have shown that a peripherally 
acting emetic stimulus (hypertonic saline infused into the 
duodenum) activates/os expression in parts of the DVC (NTS, 
AP) (8). Most of this fos expression is abolished by combined 
abdominal vagotomy and splanchnotomy (9). However, a 
significant level of fos expression persists in the activator protein-
1 after the afferent sensory pathways between the intestine and 
brain stem have been severed implying a humoral or hormonal 
effect at the level of AP. 
Another aspect of the central actions of the PP-fold family of 
peptides which can lead to divergent effects on the 
gastrointestinal motility is their widespread distribution within 
the brain, in particular NPY, which is one of the most ubiquitous 
of the neuropeptides in the mammalian brain. The highest NPY 
concentration in the rat is found in the hypothalamus. The 
parvocellular division of the paraventricular nucleus (PVN) of 
the hypothalamus is particularly densely innervated by NPY-
containing nerve terminals and fibres (10). We have shown that 
microinjection of NPY into the PVN can both inhibit and 
excite gastric acid secretion and motility depending upon the 
precise site of injection (11). The more rostral portions of the 
PVN appear to cause activation of a descending pathway to the 
DVC that stimulates vagal excitatory pathways to the stomach 
(12). In more caudal regions, NPY activates a descending 
pathway which in turn activates the intermediolateral column, 
leading to increased sympathetic activity and suppression of 
cholinergic tone through activation of a-adrenoceptors on 
intrinsic neurons (13). Thus, even one and the same peptide can 
exert opposing effects depending up on its precise locus of 
action. So far, we have only studied the receptor subtype 
involved in relation to the excitatory effects of NPY in the 
PVN, and have found, as Rogers and Hermann (1) describe for 
the DVC, that it appears to activate a Yl receptor subtype. In 
contrast to the situation in the DVC, the Y2 agonist (NPY 13-
36) had no effect on secretion or motility (12). We do not 
know yet whether the inhibitory effects of NPY in the caudal 
PVN are due to activation of a different receptor subtype. 
We have also reported various effects of PP, PYY, and NPY on 
duodenal and colonic motility and gastric secretion acting at 
sites within the thoracic spinal cord (14-16). During these 
studies, we rarely saw evidence of antagonist effect of NPY 
and PYY but this may have been due to the experimental 
conditions in that we did not use an experimental model of 
stimulated gastrointestinal activity as did Rogers and Hermann 
(1). Interestingly, however, we frequently observed biphasic 
responses (e.g. inhibition followed by excitation) with PYY. 
In summary, Rogers and Hermann provide an intriguing hypothesis 
to explain the antagonistic effects on gastric function of two 
closely related peptides acting within the DVC. In this 
Editorial Comment, I have attempted to identify some of the 
more important questions still to be addressed, and to suggest 
that similar studies are required in other areas of the CNS 
involved in the regulation of gastrointestinal function, most 
notably the hypothalamus (in particular the PVN), and the spinal 
cord. 
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